Securities code: Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) securities abbreviation: Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) Announcement No.: 2022006
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513)
Announcement of profit distribution plan in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law. Important content tips:
Distribution ratio per share: cash dividend of 7.8 yuan (including tax) will be distributed for every 10 shares, no bonus shares will be given, and no capital reserve will be converted into share capital.
The profit distribution is based on 1200900000 shares of the company’s total share capital at the end of 2021, which is subject to the announcement on the implementation of equity distribution. If the total share capital of the company changes before the equity registration date of equity distribution, it is proposed to maintain the distribution proportion per share unchanged, adjust the total distribution accordingly, and announce the specific adjustment separately.
1、 Contents of profit distribution plan
According to the audit of Zhonghui Certified Public Accountants (special general partnership), as of December 31, 2021, Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) (hereinafter referred to as “the company”) had a profit available for distribution of 50743973033 yuan at the end of the period. After deliberation and approval at the second meeting of the third board of directors, the company’s profit distribution plan for 2021 is as follows:
Based on 1200900000 shares of the company’s total share capital at the end of 2021, a cash dividend of RMB 7.8 (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of RMB 93670200 (tax included), accounting for 40.30% of the net profit attributable to shareholders of the listed company in the consolidated statements; In 2021, the company did not give bonus shares or convert capital reserve into share capital.
If the total share capital of the company changes from the date of disclosure of this announcement to the date of equity distribution and equity registration due to the conversion of convertible bonds into shares / share repurchase / share incentive grant share repurchase and cancellation / major asset restructuring share repurchase and cancellation, the company plans to maintain the distribution proportion per share unchanged and adjust the total distribution accordingly. In case of subsequent changes in the total share capital, the specific adjustment will be announced separately.
The profit distribution plan can only be implemented after being submitted to the 2021 annual general meeting of the company for deliberation and approval.
2、 Decision making procedures performed by the company
(I) convening, deliberation and voting of the board meeting
The company held the second meeting of the third board of directors on March 28, 2022, reviewed and approved the proposal on the company’s 2021 annual profit distribution plan, agreed to the profit distribution plan and agreed to submit the plan to the company’s 2021 annual general meeting for deliberation.
(II) opinions of independent directors
The independent directors of the company believe that the profit distribution plan of the company in 2021 complies with relevant laws and regulations, normative documents and relevant provisions on profit distribution in the articles of association. It is a prudent decision made in combination with the company’s profitability, future capital demand and other factors, in line with the actual situation and development needs of the company, and there is no obvious unreasonable situation such as cash out by major shareholders, There is no abuse of shareholders’ rights and improper interference in the company’s decision-making by relevant shareholders, which is in line with the interests of all shareholders of the company and will not damage the interests of minority shareholders. Therefore, we unanimously agree to the distribution plan and agree that the board of directors will submit the proposal to the 2021 annual general meeting of shareholders of the company for deliberation.
(III) opinions of the board of supervisors
The company held the second meeting of the third session of the board of supervisors on March 28, 2022, deliberated and approved the proposal on the company’s 2021 annual profit distribution plan. The board of supervisors held that the company’s 2021 annual profit distribution plan fully considered the company’s profitability, future capital demand and other factors, met the actual situation and development needs of the company, and there was no obvious unreasonable situation such as cash out by major shareholders, There is no abuse of shareholders’ rights and improper interference in the company’s decision-making by relevant shareholders, and there is no damage to the interests of minority shareholders, which is conducive to the sustainable, stable and healthy development of the company.
3、 Relevant risk tips
(I) this profit distribution plan combines the company’s profitability, future capital demand and other factors, and will not have a significant impact on the company’s operating cash flow, normal operation and long-term development.
(II) the company’s 2021 profit distribution plan needs to be submitted to the company’s 2021 annual general meeting for deliberation and approval. Please pay attention to the investment risks.
It is hereby announced.
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) board of directors
March 29, 2022
